Explore this article's sources with AI
Follow PeptideMethods on Google
Semaglutide and HFpEF heart pressures
A randomized trial found lower exercise and resting heart filling pressures with semaglutide in 81 adults with obesity-related HFpEF.
Why we wrote this. The study directly measured cardiac congestion. We explain what those pressures add to prior symptom and function results without turning a mechanistic endpoint into a cure claim.
In this article (6 sections)
A small randomized trial offers a direct look at how semaglutide affected heart filling pressures in people with obesity-related heart failure with preserved ejection fraction (HFpEF). After 52 weeks, the 81-person CAMEO-SEMA trial found lower pulmonary artery wedge pressure during exercise and at rest with semaglutide than with placebo.[1] This is mechanistic evidence about congestion. It does not show on its own that the treatment prevents hospitalization or extends life.
The finding adds a physiological explanation to earlier trial results showing improvements in symptoms, physical limitations, walking distance, and body weight in a broader HFpEF population with obesity.[3] Readers who need basic medicine context can start with our semaglutide overview and our United States semaglutide regulation guide.
What the CAMEO-SEMA trial tested
Researchers randomly assigned 81 adults with HFpEF and obesity to once-weekly semaglutide or placebo for 52 weeks. Forty-seven participants were women. The study was double-blind and placebo-controlled. Its primary outcome was the change in invasively measured pulmonary artery wedge pressure during low-intensity exercise.[1]
The trial registry describes parallel assignment, double masking of participants and investigators, and actual enrollment of 81. It identifies the study as CAMEO-SEMA and says all participants also received healthy-lifestyle counseling.[2] The semaglutide schedule belongs to the trial design. It is not a dosing recommendation.
Pulmonary artery wedge pressure is used to estimate pressure on the left side of the heart. In HFpEF, pressure can rise markedly with activity even when the heart's ejection fraction remains preserved. Measuring it through catheterization during exercise gives a more direct view of congestion than symptoms or body weight alone.
Exercise filling pressure fell
At baseline, average wedge pressure was 17.5 mmHg at rest and 31.7 mmHg during exercise. Over 52 weeks, exercise wedge pressure changed by minus 9.8 mmHg in the semaglutide group and plus 0.9 mmHg in the placebo group. The estimated between-group difference was minus 10.6 mmHg, with a 95% confidence interval from minus 13.3 to minus 8.0.[1]
Resting wedge pressure also fell relative to placebo. The estimated difference was minus 7.1 mmHg, with a 95% confidence interval from minus 9.8 to minus 4.4. Both reported pressure comparisons had P values below 0.0001.[1]
These are substantial hemodynamic differences within this selected trial population. The result is stronger than a before-and-after observation because assignment was randomized and the comparison used placebo. It still needs to be interpreted according to the measured endpoint: filling pressure is a physiological marker, not a count of heart failure events.
More participants met the trial's remission definition
The researchers defined hemodynamic HFpEF remission as normal wedge pressure at both rest and exercise at week 52. By that study definition, 53.7% of semaglutide participants and 7.4% of placebo participants met the threshold. The reported odds ratio was 14.1, but its 95% confidence interval was wide, from 3.0 to 134.6.[1]
The word remission needs care here. It refers to a prespecified hemodynamic definition at one follow-up point. It does not mean HFpEF was permanently cured, that symptoms disappeared in every participant, or that future clinical risk returned to that of a person without heart failure. The wide confidence interval also reflects uncertainty from the small sample.
How this fits the earlier STEP-HFpEF evidence
The earlier STEP-HFpEF randomized trial enrolled 529 people with HFpEF and a body-mass index of at least 30. At 52 weeks, the Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 16.6 points with semaglutide and 8.7 points with placebo, an estimated difference of 7.8 points. Average body weight changed by minus 13.3% and minus 2.6%, respectively.[3]
STEP-HFpEF also reported an estimated 20.3-meter between-group improvement in six-minute walk distance. That larger trial focused on symptoms, physical function, and weight rather than invasive exercise hemodynamics.[3] CAMEO-SEMA therefore helps connect patient-facing changes with a plausible change in cardiac congestion, but it should not be treated as a replication of every STEP-HFpEF endpoint.
The studies are complementary rather than interchangeable. They enrolled different groups, used different primary outcomes, and were not designed as one combined comparison. The new pressure findings make the biological story more coherent. They do not prove that pressure reduction accounts for every symptom or functional change seen in the larger program.
What the trial cannot establish
CAMEO-SEMA was too small and too focused on physiology to establish effects on hospitalization, cardiovascular death, or overall survival. The abstract does not provide a full adverse-event table, discontinuation breakdown, or enough subgroup data to know whether the pressure response was consistent across sex, diabetes status, or baseline congestion severity.
The trial's registry lists completion in July 2026 and describes a single-center Mayo Clinic study.[2] Results from one specialized center may not transfer cleanly to less selected patients, people with different causes of HFpEF, or those who could not undergo invasive exercise testing.
Weight loss may contribute to improved hemodynamics, but this report alone cannot separate weight-mediated effects from other actions of semaglutide. A mediation analysis or a trial designed to match weight change across interventions would be needed to answer that question more directly.
What we do not yet know
We do not yet know whether the pressure changes persist beyond one year, whether they predict fewer heart failure admissions, or which patients are most likely to reach the study's hemodynamic remission threshold. The durability of the result after stopping treatment is also unknown from the reported abstract.
Larger multicenter studies with clinical outcomes would help establish whether invasive pressure improvement translates into better long-term health. Until then, this trial is best read as evidence that semaglutide changed a central feature of obesity-related HFpEF physiology in a small randomized sample, not as proof of cure or a stand-alone treatment instruction.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What did the CAMEO-SEMA trial find?
After 52 weeks, semaglutide reduced pulmonary artery wedge pressure during exercise and at rest compared with placebo in 81 adults with obesity-related HFpEF.
Does hemodynamic remission mean HFpEF was cured?
No. It was the trial's definition for normal wedge pressure at rest and exercise at week 52. It does not establish a permanent cure or removal of future heart failure risk.
Did this trial show fewer hospitalizations or deaths?
No. The study was designed around invasive pressure measurements and was too small to establish effects on hospitalization, cardiovascular death, or survival.
How does this differ from STEP-HFpEF?
STEP-HFpEF was a larger randomized trial centered on symptoms, physical limitations, body weight, and walking distance. CAMEO-SEMA used invasive exercise testing to examine cardiac filling pressure.
Sources
No revisions yet. First published .